Press release from the therapeutic doctor (NASDAQ:TXMD): Fiscal year net loss from continuing operations was $7.7 million, or $0.74 per basic and diluted share, compared to net income from continuing operations of $1.1 million, or $0.12 per basic share and $0.11 per diluted share, for 2022.
Gross licensing royalties are approximately $4.5 million under the Mayne licensing agreement for the full year ended December 31, 2023.
As of December 31, 2023, the Company’s cash and cash equivalents were $4.3 million.
The Company said it continues to evaluate a number of strategic alternatives that may include, but not be limited to, acquisition, merger, other business combinations, asset sales or other strategic transactions involving the Company.